References
- Ellingson KD, Sapiano MRP, Haass KA, et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion. 2017;57(2):1588–1598.
- Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116(22):2544–2552.
- Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010;50(4):753–765.
- Shander A, Ozawa S, Hofmann A. Activity-based costs of plasma transfusions in medical and surgical inpatients at a US hospital. Vox Sang. 2016;111(1):55–61.
- Velasquez CA, Singh M, Bin Mahmood SU, et al. The effect of blood transfusion on outcomes in aortic surgery. Int J Angiol. 2017;26(3):135–142.
- Bracey A, Shander A, Aronson S, et al. The use of topical hemostatic agents in cardiothoracic surgery. Ann Thorac Surg. 2017;104(1):353–360.
- Singh RK, Baumgartner B, Mantei JR, et al. Hemostatic comparison of a polysaccharide powder and a gelatin powder. J Invest Surg. 2018;1–9.
- Mourad FH, Leong RW. Role of hemostatic powders in the management of lower gastrointestinal bleeding: A review. J Gastroenterol Hepatol. 2018;33(8):1445–1453.
- MacDonald MH, Wang AY, Clymer JW, Hutchinson RW, Kocharian R. An in vivo comparison of the efficacy of hemostatic powders, using two porcine bleeding models. Med Devices (Auckl). 2017;10:273–279.
- Biom'Up SA. HEMOBLAST Bellows hemostatic agent. Published 2018 Jan [cited 2018, Nov 15]. Available from: https://www.hemoblast.com/content/uploads/2018/02/ifu-us-2018.pdf.
- Business W. Biom’Up receives FDA marketing approval for HEMOBLAST Bellows, its flagship product. Published 2017 Dec 18 [cited 2018 Nov 15]. https://www.businesswire.com/news/home/20171217005101/en/Biom%E2%80%99Up-Receives-FDA-Marketing-Approval-HEMOBLAST%E2%84%A2-Bellows. Available from: https://www.biomup.com/file/0654/pr-18-12-17.PDF.
- Echave M, Oyaguez I, Casado MA. Use of Floseal(R), a human gelatine-thrombin matrix sealant, in surgery: a systematic review. BMC Surg. 2014;14:111.
- Tackett SM, Calcaterra D, Magee G, Lattouf OM. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothorac Vasc Anesth. 2014;28(6):1558–1565.
- Oz MC, Cosgrove DM, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg. 2000;69(5):1376–1382.
- Watrowski R, Jager C, Forster J. Improvement of perioperative outcomes in major gynecological and gynecologic-oncological surgery with hemostatic gelatin-thrombin matrix. IV. 2017;31(2):251–258.
- Weaver FA, Hood DB, Zatina M, Messina L, Badduke B. Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery. Ann Vasc Surg. 2002;16(3):286–293.
- Baxter Healthcare C. Baxter Healthcare SA. FLOSEAL Hemostatic Matrix, instructions for use. Published 2015 Apr 04 [cited 2018 Nov 15]. Available from: http://www.floseal.com/int/instructions-for-use.html.
- Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88(5):1520–1526.
- Ereth MH, Schrader LM, Dong Y, et al. Efficacy of microporous polysaccharide hemospheres on liver punch biopsies porcine model. Anesthesiology Annual Meeting. 2003. A153. San Francisco, CA: American Society of Anesthesiologists. CrossRef]
- US National Research Council. Guide for the care and use of laboratory animals. 8th edition. Washington (DC): National Academies Press (US); 2011.
- Spotnitz WD, Zielske D, Centis V, et al. The SPOT GRADE: a new method for reproducibly quantifying surgical wound bleeding. Spine (Phila Pa 1976). 2018;43(11):E664–E671.
- Lewis KM, Li Q, Jones DS, et al. Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents. Surgery. 2017;161(3):771–781.
- Coenye KE, Bourgain C, Keibl C, Nurnberger S, van Griensven M. A qualitative morphological comparison of two haemostatic agents in a porcine liver trauma model. SS. 2013;4(8):359–364.
- Lewis KM, Atlee HD, Mannone AJ, et al. Comparison of two gelatin and thrombin combination hemostats in a porcine liver abrasion model. J Invest Surg. 2013;26(3):141–148.
- Agency EM. Committee for medicinal products for human use. Consultation Procedure Public Assessment Report (CPAR): Consultation on an ancillary medicinal substance incorporated in a medical device. EMA/66720/2015. Published 2014 Sep 25 [cited 2018 Nov 15]. Available from: https://www.ema.europa.eu/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-hemoblast_en.pdf.
- Lewis KM, Atlee H, Mannone A, Lin L, Goppelt A. Efficacy of hemostatic matrix and microporous polysaccharide hemospheres. J Surg Res. 2015;193(2):825–830.